CF PharmTech. Inc. Class H (2652) Stock Price & Analysis

2652 Stock Chart & Stats

HK$5.30-HK$0.33(-5.86%)

At close: Oct 30 4:00 PM GMT+8

Day’s Range: HKD 5.27 - HKD 5.78
52-Week Range: HKD 5.18 - HKD 39.50
Previous Close: HKD 5.63
Volume: N/A
Average Volume (3M): 2.84M
Market Cap: HKD 2.30B
Enterprise Value: HKD 8.28B
Total Cash (Recent Filing): N/A
Total Debt (Recent Filing): N/A
Price to Earnings (P/E): ―
Beta: 0.72
Next Earnings: N/A
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

CF PharmTech. Inc. Class H News

CF PharmTech Core Management Voluntarily Extends Share Lock-Up by Six Months

CF PharmTech. Inc. Class H ( ($HK:2652) ) just unveiled an announcement. CF PharmTech has announced that co-founders and core managers Dr. Liang Bill Wenqing and Dr. Li Li Bovet

3w ago2652

CF PharmTech Advances Inhaled ILD Drug ICF004 With First Dosing in Phase I Trial

CF PharmTech. Inc. Class H ( ($HK:2652) ) has provided an announcement. CF PharmTech has reported a key milestone in the development of ICF004, an inhalation powder for treating interstitial

1M ago2652

CF PharmTech Wins Expanded Trial Approvals for Inhaled Lung Disease Candidate ICF001

An update from CF PharmTech. Inc. Class H ( ($HK:2652) ) is now available. CF PharmTech has received implied clinical trial approvals from China’s National Medical Products Administration to expand

2M ago2652

CF PharmTech Board to Review Interim Results and Consider Dividend

The latest announcement is out from CF PharmTech. Inc. Class H ( ($HK:2652) ). CF PharmTech, Inc., a Hong Kong-listed Chinese pharmaceutical company, has announced that its board of directors

2M ago2652

CF PharmTech completes HK$13.82 H-share placing to broaden investor base

CF PharmTech. Inc. Class H ( ($HK:2652) ) has provided an update. CF PharmTech, Inc., a PRC-based pharmaceutical company listed in Hong Kong via H shares, continues to leverage the

2M ago2652

CF PharmTech Launches Discounted HK$300 Million H-Share Placing

CF PharmTech. Inc. Class H ( ($HK:2652) ) has shared an announcement. CF PharmTech, Inc. has agreed to place 21,747,700 new H shares through a syndicate of placing agents under

3M ago2652

CF PharmTech AGM Approves 2025 Results and Elects New Board

The latest update is out from CF PharmTech. Inc. Class H ( ($HK:2652) ). CF PharmTech reported that all resolutions at its June 26 annual general meeting were passed by

4M ago2652

CF PharmTech details board and committee structure

CF PharmTech. Inc. Class H ( ($HK:2652) ) has shared an update. CF PharmTech, Inc. announced the current composition of its board of directors, identifying chairperson Dr. Liang Bill Wenqing

4M ago2652

CF PharmTech cuts H-share board lot size to boost liquidity

CF PharmTech. Inc. Class H ( ($HK:2652) ) has provided an announcement. CF PharmTech, Inc. will reduce the board lot size of its H shares traded on the Hong Kong

4M ago2652

CF PharmTech Wins PIC/S GMP Clearance for Suzhou Inhalation Plant

CF PharmTech. Inc. Class H ( ($HK:2652) ) has shared an update. CF PharmTech has reported that its Suzhou inhalation formulation production base has passed a good manufacturing practice inspection

5M ago2652

2652 FAQ

What was CF PharmTech. Inc. Class H’s price range in the past 12 months?

CF PharmTech. Inc. Class H lowest stock price was HK$5.18 and its highest was HK$39.50 in the past 12 months.

What is CF PharmTech. Inc. Class H’s market cap?

CF PharmTech. Inc. Class H’s market cap is HK$2.30B.

When is CF PharmTech. Inc. Class H’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were CF PharmTech. Inc. Class H’s earnings last quarter?

CF PharmTech. Inc. Class H released its earnings results on Aug 31, 2026. The company reported -HK$0.03 earnings per share for the quarter.

Is CF PharmTech. Inc. Class H overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does CF PharmTech. Inc. Class H pay dividends?

CF PharmTech. Inc. Class H does not currently pay dividends.

What is CF PharmTech. Inc. Class H’s EPS estimate?

CF PharmTech. Inc. Class H’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does CF PharmTech. Inc. Class H have?

CF PharmTech. Inc. Class H has 323,971,280 shares outstanding.

What happened to CF PharmTech. Inc. Class H’s price movement after its last earnings report?

CF PharmTech. Inc. Class H reported an EPS of -HK$0.03 in its last earnings report. Following the earnings report the stock price went down -2.895%.

Which hedge fund is a major shareholder of CF PharmTech. Inc. Class H?

Currently, no hedge funds are holding shares in HK:2652

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

CF PharmTech. Inc. Class H Stock Smart Score

Underperform

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

CF PharmTech. Inc. Class H

CF PharmTech, Inc. engages in research and development, production, and sale of respiratory drugs and other related medical products in China. It offers Shufeimin, an azelastine hydrochloride and fluticasone propionate nasal spray; ChangQi, a budesonide inhalation suspension solution; ChangShu, a salbutamol sulfate inhalation solution; and piezoelectric mesh nebulizer, electric nasal cleaner, BFS hypertonic and physiological seawater nasal cleansing fluid products under the ChangShu name. The company also develops products for the treatment of respiratory diseases, including allergic rhinitis, asthma, chronic obstructive pulmonary, respiratory infection, pulmonary fibrosis, pulmonary hypertension, and other respiratory diseases. In addition, it develops therapeutic products for respiratory and other diseases, such as inhalation spray and aerosol, dry powder inhaler, nebulization, nasal spray products, as well as liposomes. Further, the company provides CDMO/CMO technical services. CF PharmTech, Inc. was formerly known as Suzhou CF PharmTech Co., Ltd. CF PharmTech, Inc. was founded in 2007 and is based in Suzhou, China.

CF PharmTech. Inc. Class H (2652) Earnings & Revenues

Historic Earnings Reports

Technical Analysis

Overall Consensus

Indicator	Bullish	Neutral	Bearish
Overall Consensus	3	4	15
Technical Analysis	3	4	3
Moving Averages	0	0	12

Technical Analysis >

Similar Stocks

Stocks similar to HK:2652
Company	Price & Change	Follow
HK:0858Extrawell Pharmaceutical Holdings Limited
HK:0455Tianda Pharmaceuticals Ltd.
HK:0950Lee's Pharmaceutical Holdings Limited
HK:2633Jacobson Pharma Corporation Limited
HK:6833Sinco Pharmaceuticals Holdings Ltd.

Compare HK:2652 Stocks >

Ownership Overview

99.98% Public Companies and Individual Investors

Detailed Ownership Overview >

Popular Stocks

Popular Stocks
Company	Price & Change	Follow
NVDANvidia
AAPLApple
MSFTMicrosoft

2652 Stock Chart & Stats

CF PharmTech. Inc. Class H News

CF PharmTech Core Management Voluntarily Extends Share Lock-Up by Six Months

CF PharmTech Advances Inhaled ILD Drug ICF004 With First Dosing in Phase I Trial

CF PharmTech Wins Expanded Trial Approvals for Inhaled Lung Disease Candidate ICF001

CF PharmTech Board to Review Interim Results and Consider Dividend

CF PharmTech completes HK$13.82 H-share placing to broaden investor base

CF PharmTech Launches Discounted HK$300 Million H-Share Placing

CF PharmTech AGM Approves 2025 Results and Elects New Board

CF PharmTech details board and committee structure

CF PharmTech cuts H-share board lot size to boost liquidity

CF PharmTech Wins PIC/S GMP Clearance for Suzhou Inhalation Plant

2652 FAQ

CF PharmTech. Inc. Class H Stock Smart Score

Company Description

CF PharmTech. Inc. Class H

CF PharmTech. Inc. Class H (2652) Earnings & Revenues

Technical Analysis

Overall Consensus

Similar Stocks

Ownership Overview

Popular Stocks

Become an Expert with TipRanks Premium